Eram Khan

Eram Khan is a partner in Goodwin’s Antitrust and Competition practice, based in London. She has over a decade of experience working across the spectrum of competition law issues.

Eram advises clients across all sectors, with a particular focus on healthcare, life sciences, energy, commodities, financial services and private equity. She has been a key adviser to major corporates, investment banks, institutional investors, and PE houses on their most challenging international transactions, with specific expertise in EU, UK and multi-jurisdictional merger control, foreign investment control, and behavioural antitrust issues.

Eram has extensive experience advising leniency applicants in EC cartel investigations, compliance work, and market studies carried out by competition and financial regulatory authorities in the EU and the UK.

She has previously worked in Brussels for a period of two years as well as in-house on a secondment with the Competition team of a leading retail bank in the UK.

Eram’s representative experience includes advising:

• Eidos Therapeutics and BridgeBio International GmbH in their exclusive license agreement to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in Europe with Bayer Consumer Care AG
• Isovalent Inc., a cloud native networking and security solutions provider, on its acquisition by Cisco Systems, Inc
• The Telegraph Media Group and the independent directors on its Board in connection with the public interest review of its proposed acquisition by Redbird IMI
• TA Associates and Warburg Pincus on their investment in Epassi Group, a leading digital payments provider for employee benefits, from Bregal Milestone, and subsequent combination with the Exercite Group, a B2B fitness platform previously owned by Waterland
• Envato, a leading online platform for creative assets and tools, on its agreement to sell its entire issued share capital to Shutterstock
• Arlington Capital Partners in the sale of its portfolio company, BlueHalo, to AeroVironment, Inc.
• TA Associates on its acquisition of a majority stake in Solifi, a global fintech software provider for secured finance, from existing investor Thoma Bravo
• Versanis Bio on its acquisition by Eli Lilly for up to $1.925 billion
• Inversago Pharma on its $1.7 billion acquisition by Novo Nordisk
• Globus Medical, a leading musculoskeletal solutions company, in its definitive agreement to combine in an all-stock transaction with NuVasive
• TCR2 Therapeutics on its strategic combination with Adaptimmune Therapeutics to create a preeminent cell therapy company focused on treating solid tumors
• Qualtrics International on its $12.5 billion sale to Silver Lake and CCP Investments
• SunMed Group on its definitive agreement to acquire the respiratory health business of Avanos Medical, Inc.
• SSE Thermal and Equinor on their acquisition of Triton Power Holdings Ltd from Energy Capital Partners*
• Glencore on the multi-jurisdictional merger control clearances for its acquisition of its remaining stake in the Cerrejón coal mine in Colombia from its joint venture partners, Anglo American and BHP*
• Alinda Capital Partners on the sale of its majority stake in Energy Assets Group, a UK-based metering and energy service business, to an international consortium buyer*
• Jingye Group, a Chinese steel company, on the merger control aspects of its acquisition of certain assets of British Steel*
• Advent International on the merger control clearances for its ₤1 billion recommended cash offer for Laird*
• Cerberus Capital Management on its acquisition of Worldwide Flight Services, one of the world’s leading providers of air cargo and ground handling services*
• Lloyds Banking Group on the acquisition of Tesco Bank’s prime ₤3.7 billion UK residential mortgage portfolio and the acquisition of Zurich’s UK workplace pensions and savings business*
• Deutsche Börse on the European Commission’s in-depth investigation into its proposed ₤21 billion merger with the London Stock Exchange Group*
• Novartis on the merger clearances for its transformational three-way asset swap with GSK, involving the acquisition by Novartis of GSK’s oncology business, the sale to GSK of Novartis’ vaccines business (excluding influenza vaccines) and the creation of a joint venture in consumer health products with GSK (GCR Matter of the Year and FT Innovative Lawyers Award)*
• Glencore on various merger control and competition law compliance matters, including its $70 billion acquisition of the remaining stake in Xstrata and on their $775.2 million sale of a 51% stake in its global oil storage business to HNA*
• An automotive parts company as the immunity applicant in the European Commission’s investigation concerning various automotive components, forming part of what has been described as the “largest cartel investigation in history”*

*Denotes experience prior to joining Goodwin

Eram is a member of The Competition Section, Law Society of England & Wales. She is also a member of the Antitrust Sections of the American Bar Association and the International Bar Association

Prior to joining Goodwin, Eram was counsel at Linklaters LLP in London.

Eram has been recognized as a ‘Future Leader’ by Who’s Who Legal Competition in (2020-2024) guides.